Stock MMQ MIND MEDICINE (MINDMED) INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Mind Medicine (MindMed) Inc. Deutsche Boerse AG

Equities

MMQ

CA60255C8850

Market Closed - Deutsche Boerse AG
Other stock markets
 07:11:41 08/05/2024 BST 		5-day change 1st Jan Change
8.815 EUR +1.61% Intraday chart for Mind Medicine (MindMed) Inc. +4.94% +160.49%
04-15 Leerink Partners Starts Mind Medicine (MindMed) With Outperform Rating, $20 Price Target MT
03-18 Mind Medicine Inc. announced that it has received $75 million in funding from Deep Track Capital, LP, Commodore Capital CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
MindMed Reports First Quarter 2024 Financial Results and Business Updates
BU
MindMed ISPOR 2024: Work Productivity and Activity Impairment Associated with Generalized Anxiety Disorder among Adults in the United States
PU
MindMed ISPOR 2024: Health-related Quality of Life Associated with Generalized Anxiety Disorder among Adults in the United States
PU
MindMed ISPOR 2024: Health Care Resource Use Associated with Generalized Anxiety Disorder among Adults in the United States
PU
MindMed APA 2024: Screening Adults in the US General Population to Detect Cases of Undiagnosed Generalized Anxiety Disorder
PU
MindMed Presents Phase 2b Study of MM120 for Generalized Anxiety Disorder (GAD) at American Psychiatric Association (APA) Annual Meeting in New York
BU
MindMed to Host Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Business Update
BU
MindMed to Present at Upcoming May Medical Conferences
BU
Leerink Partners Starts Mind Medicine (MindMed) With Outperform Rating, $20 Price Target
MT
MindMed to Present at Upcoming April Medical Conferences
BU
MindMed Announces Voluntary Delisting from Cboe Canada
BU
Mind Medicine Inc. announced that it has received $75 million in funding from Deep Track Capital, LP, Commodore Capital
CI
MindMed to Participate in the Leerink Partners 2024 Global Biopharma Conference
BU
RBC Raises Price Target on Mind Medicine (MindMed) to $22 From $15, Keeps Outperform, Speculative Risk
MT
Numinus Wellness Congratulates Mindmed on Positive Results from Phase 2B Clinical Trials of Mm120 for Generalized Anxiety Disorder
CI
Sector Update: Health Care Stocks Gain Late Afternoon
MT
Sector Update: Health Care Stocks Stronger in Afternoon Trading
MT
Roth MKM Raises Price Target on Mind Medicine to $36 From $25, Keeps Buy Rating
MT
Mind Medicine Gets FDA Breakthrough for Anxiety Treatment, Sees $175 Million in Proceeds From Stock Offerings; Shares Jump
MT
Mind Medicine MindMed : Investor Presentation - MM120 for Generalized Anxiety Disorder Conference Call and Webcast
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MNMD Stock
  4. MMQ Stock
  5. News Mind Medicine (MindMed) Inc.